SCHEMBL3360913

SCHEMBL3360913

Cc1cc(-c2ccc(C=O)cc2)ccc1C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.46
ALDH1A1 P00352 4/20 0.43
TSHR P16473 1/20 0.43
KIF11 P52732 1/20 0.43
TYR P14679 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
PTK2B Q14289 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DRD1 P21728 2/20 0.40
PKM P14618 1/20 0.40
BRD4 O60885 1/20 0.40
CYP2A13 Q16696 1/20 0.38
IP6K1 Q92551 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11869494 0.89 ALDH1A1 (0.52) ALDH1A1TSHRTYRNPC1RAB9A
SCHEMBL29918523 0.89 ALDH1A1 (0.52) ALDH1A1TSHRTYRNPC1RAB9A
SCHEMBL30302136 0.84 ALDH1A1 (0.54) ALDH1A1TSHRNPC1RAB9AKDM4E
SCHEMBL5265352 0.84 ALDH1A1 (0.54) ALDH1A1TSHRNPC1RAB9AKDM4E
SCHEMBL3456595 0.83 CYP2A6 (0.50) CYP2A6ALDH1A1TSHRKIF11TYR
SCHEMBL823127 0.83 ALDH1A1 (0.50) CYP2A6ALDH1A1TSHRTYRNPC1
SCHEMBL2605776 0.83 ALDH1A1 (0.44) CYP2A6ALDH1A1TSHRKIF11TYR
SCHEMBL31227833 0.82 TNKS2 (0.47) ALDH1A1TSHRNPC1RAB9AKDM4E
SCHEMBL4889825 0.82 ERN1 (0.50) ALDH1A1TSHRTYRMEN1KMT2A
SCHEMBL21953737 0.78 DAPK3 (0.44) ALDH1A1TSHRNPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117327243-B Olefin-linked two-dimensional covalent organic framework, and preparation method and application thereof 天津师范大学 2024-04-30 CN claimed
CN-117327243-A Olefin-linked two-dimensional covalent organic framework, and preparation method and application thereof 天津师范大学 2024-01-02 CN claimed
CN-117327243-B Olefin-linked two-dimensional covalent organic framework, and preparation method and application thereof 天津师范大学 2024-04-30 CN disclosed
CN-117327243-A Olefin-linked two-dimensional covalent organic framework, and preparation method and application thereof 天津师范大学 2024-01-02 CN disclosed
US-7649015-B2 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. (US) 2010-01-19 US disclosed
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds GILEAD SCIENCES, INC. 2007-01-11 US disclosed
EP-1711617-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-10-18 EP disclosed
WO-2005064008-A9 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES INC (US) 2006-09-28 WO disclosed
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds GILEAD SCIENCES. INC. 2005-10-27 US disclosed
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. 2005-09-22 US disclosed
WO-2005064008-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-07-14 WO disclosed
EP-1509537-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2005-03-02 EP disclosed
WO-2003090690-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds PPA1, PPME1, PNP CYP2A6 3590/4885ALDH1A1 3361/4885TSHR 4770/4885
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds CES1, PNP, PGLS CYP2A6 811/4885ALDH1A1 3232/4885TSHR 4748/4885
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds PPA1, PNP, PPME1 CYP2A6 3430/4885ALDH1A1 3337/4885TSHR 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.